Jasper Therapeutics (NASDAQ:JSPR) Price Target Cut to $48.00 by Analysts at Royal Bank of Canada

Jasper Therapeutics (NASDAQ:JSPR) had its target price lowered by Royal Bank of Canada from $68.00 to $48.00 in a report released on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the stock.

A number of other research firms also recently weighed in on JSPR. HC Wainwright restated a “buy” rating and set a $65.00 price target on shares of Jasper Therapeutics in a report on Thursday, October 24th. BMO Capital Markets initiated coverage on shares of Jasper Therapeutics in a research report on Friday, December 6th. They set an “outperform” rating and a $63.00 target price on the stock. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $70.00 price target on shares of Jasper Therapeutics in a research report on Monday, January 6th. Ten research analysts have rated the stock with a buy rating, According to data from MarketBeat, Jasper Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $67.75.

Jasper Therapeutics Stock Performance

Shares of JSPR opened at $7.05 on Thursday. The firm has a market cap of $105.76 million, a PE ratio of -1.49 and a beta of 2.18. The firm’s 50 day moving average price is $21.37 and its 200 day moving average price is $20.27. Jasper Therapeutics has a twelve month low of $6.57 and a twelve month high of $31.01.

Institutional Trading of Jasper Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets lifted its holdings in shares of Jasper Therapeutics by 208.6% during the third quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock worth $47,000 after buying an additional 1,698 shares during the last quarter. Wolff Wiese Magana LLC bought a new position in Jasper Therapeutics during the third quarter worth $59,000. MetLife Investment Management LLC raised its stake in Jasper Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock valued at $129,000 after purchasing an additional 3,873 shares during the last quarter. Jane Street Group LLC bought a new stake in Jasper Therapeutics in the 3rd quarter valued at $251,000. Finally, Rhumbline Advisers acquired a new stake in Jasper Therapeutics in the 2nd quarter worth $300,000. Institutional investors and hedge funds own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.